title: [The effect of an antihypertensive drug budralazine on cerebrovascular lesions in salt-loaded SHR].
abstract: Budralazine was evaluated for its protective effect on the onset of cerebrovascular lesions in SHR given 1.5% NaCl as drinking water. The salt-loading for 67 days rapidly accelerated the development of hypertension in SHR (from 180 to over 250 mmHg, 40 days after the loading). The acceleration of hypertension was accompanied by an increase in the incidence of brain softening, cerebral infarct, angionecrosis and hemorrhage by 30-60% following the thrombosis and necrosis of cerebral arterioles. Renal angionecrosis associated with the interstitial nephrosis was also observed by 90% in the animals. Throughout the salt-loading period, oral administration of budralazine (1, 4 and 15 mg/kg/day) resulted in a dose-dependent inhibition of the accelerated hypertension. At larger doses (4 and 15 mg/kg/day), budralazine almost completely ameliorated the cerebral and renal lesions and significantly attenuated the rise of weight in the brain and heart observed in the salt-loaded control rats. Changes in the serum biochemical findings were also inhibited by this drug. In some of the parameters measured, budralazine appeared to be more efficacious than hydralazine (1, 4 and 15 mg/kg/day, p.o.). These results suggest that budralazine attenuates the serious development of hypertension and reduces the incidence and severity of stroke in salt-loaded SHR.
authors: Laboratory of Pharmacology, Research Institute, Daiichi Seiyaku Co., Ltd., Tokyo, Japan.
authors: S
authors: S
authors: Tanaka
authors: M
authors: M
authors: Ishihara
authors: S
authors: S
authors: Shibamura
authors: F
authors: F
authors: Sekiguchi
authors: M
authors: M
authors: Hirohashi
authors: Y
authors: Y
authors: Shirasaki
authors: A
authors: A
authors: Akashi
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000473:pathology; D002561:Cerebrovascular Disorders / Q000473:pathology / Q000517:prevention & control*; D006830:Hydralazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011918:Rats, Inbred SHR; D012965:Sodium Chloride
chemical_list: D000959:Antihypertensive Agents; D006830:Hydralazine; D012965:Sodium Chloride; C006153:budralazine